Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768079 | 0.92 | HRH3 (0.84) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL8250806 | 0.86 | TP53 (0.61) | HRH3CNR2 | |
| SCHEMBL8252162 | 0.86 | HRH3 (0.63) | HRH3PYCR1 | |
| SCHEMBL12680476 | 0.84 | HRH3 (1.00) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL25541295 | 0.83 | HRH3 (0.52) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL13222337 | 0.83 | HRH3 (0.52) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL8244555 | 0.83 | MAPT (0.61) | HRH3 | |
| SCHEMBL2253179 | 0.82 | HRH3 (0.70) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL5925786 | 0.82 | HRH3 (0.70) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL26686938 | 0.82 | HRH3 (0.70) | HRH3HDAC8HDAC6PYCR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7696355-B2 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | BAYER AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7696355-B2 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | BAYER AKTIENGESELLSCHAFT (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-20080132474-A1 | BREAST CANCER SCREENING AND TREATMENT METHODS | GENE LOGIC INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070232670-A1 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | BAYER AKTIENGESELLSCHAFT (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232670-A1 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | BAYER AKTIENGESELLSCHAFT (DE) | 2007-10-04 | — | — | US | disclosed |
| US-7157481-B2 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | BAYER AKTIENGESELLSCHAFT (DE) | 2007-01-02 | — | — | US | disclosed |
| US-7157481-B2 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | BAYER AKTIENGESELLSCHAFT (DE) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | HRH3 513/4885HDAC8 3188/4885HDAC6 1919/4885 |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | HRH3 1065/4885HDAC8 3132/4885HDAC6 2460/4885 |
| US-20070232670-A1 | Isothiazole carboxylic acid amides and the application thereof in order to protect plants | CAT, AADAC, CBR3 | HRH3 279/4885HDAC8 244/4885HDAC6 11/4885 |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | HRH3 548/4885HDAC8 3446/4885HDAC6 2319/4885 |
| US-20080132474-A1 | BREAST CANCER SCREENING AND TREATMENT METHODS | PGR, AGTR1, AGTR2 | HRH3 1088/4885HDAC8 2546/4885HDAC6 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.